Galmed Pharmaceuticals (GLMD) Competitors

$0.63 +0.04 (+6.41%)

Closing price 05/6/2026 04:00 PM Eastern

Extended Trading

$0.62 -0.01 (-1.08%)

As of 05:30 AM Eastern

GLMD vs. AIMD, BCDA, CLRB, MDCX, and GDTC

Should you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Ainos (AIMD), BioCardia (BCDA), Cellectar Biosciences (CLRB), Medicus Pharma (MDCX), and CytoMed Therapeutics (GDTC). These companies are all part of the "pharmaceutical products" industry.

How does Galmed Pharmaceuticals compare to Ainos?

Ainos (NASDAQ:AIMD) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

: Ainos has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ainos
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Galmed Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 9.8% of Ainos shares are owned by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: Galmed Pharmaceuticals has lower revenue, but higher earnings than Ainos. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ainos $120K 107.23 -$14.77M -$3.53 N/A
Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A
: Galmed Pharmaceuticals has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Galmed Pharmaceuticals' return on equity of -29.43% beat Ainos' return on equity.
Company Net Margins Return on Equity Return on Assets
Ainos -11,912.10% -140.10% -62.97%
Galmed Pharmaceuticals N/A -29.43% -26.00%
: In the previous week, Ainos had 1 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 2 mentions for Ainos and 1 mentions for Galmed Pharmaceuticals. Ainos' average media sentiment score of 1.00 beat Galmed Pharmaceuticals' score of 0.00 indicating that Ainos is being referred to more favorably in the media.
Company Overall Sentiment
Ainos Positive
Galmed Pharmaceuticals Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	107.23	-$14.77M	-$3.53	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-140.10%	-62.97%
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%

Company	Overall Sentiment
Ainos	Positive
Galmed Pharmaceuticals	Neutral

Summary

Galmed Pharmaceuticals beats Ainos on 7 of the 12 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to BioCardia?

Galmed Pharmaceuticals (NASDAQ:GLMD) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

: 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Comparatively, 17.4% of BioCardia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: Galmed Pharmaceuticals has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.
: BioCardia has higher revenue and earnings than Galmed Pharmaceuticals. BioCardia is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A
BioCardia $60K 202.39 -$8.23M -$1.29 N/A
: BioCardia has a consensus price target of $25.00, suggesting a potential upside of 2,152.25%. Given BioCardia's stronger consensus rating and higher possible upside, analysts clearly believe BioCardia is more favorable than Galmed Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galmed Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
BioCardia
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Galmed Pharmaceuticals' return on equity of -29.43% beat BioCardia's return on equity.
Company Net Margins Return on Equity Return on Assets
Galmed Pharmaceuticals N/A -29.43% -26.00%
BioCardia N/A -28,372.40% -238.22%
: In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than BioCardia. MarketBeat recorded 1 mentions for Galmed Pharmaceuticals and 0 mentions for BioCardia. Galmed Pharmaceuticals' average media sentiment score of 0.00 equaled BioCardia'saverage media sentiment score.
Company Overall Sentiment
Galmed Pharmaceuticals Neutral
BioCardia Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A
BioCardia	$60K	202.39	-$8.23M	-$1.29	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%
BioCardia	N/A	-28,372.40%	-238.22%

Company	Overall Sentiment
Galmed Pharmaceuticals	Neutral
BioCardia	Neutral

Summary

Galmed Pharmaceuticals beats BioCardia on 8 of the 13 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

: Cellectar Biosciences presently has a consensus price target of $11.00, indicating a potential upside of 211.61%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Cellectar Biosciences is more favorable than Galmed Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectar Biosciences
1 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
Galmed Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Cellectar Biosciences has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.
: 16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 5.0% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: Galmed Pharmaceuticals' return on equity of -29.43% beat Cellectar Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Cellectar Biosciences N/A -298.05% -144.59%
Galmed Pharmaceuticals N/A -29.43% -26.00%
: In the previous week, Cellectar Biosciences had 6 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 7 mentions for Cellectar Biosciences and 1 mentions for Galmed Pharmaceuticals. Cellectar Biosciences' average media sentiment score of 0.05 beat Galmed Pharmaceuticals' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cellectar Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Galmed Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cellectar Biosciences N/A N/A -$21.79M -$9.53 N/A
Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-298.05%	-144.59%
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Galmed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$9.53	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A

Summary

Galmed Pharmaceuticals beats Cellectar Biosciences on 7 of the 13 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Medicus Pharma?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

: Medicus Pharma has a consensus price target of $14.50, indicating a potential upside of 4,259.59%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Medicus Pharma is more favorable than Galmed Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galmed Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Medicus Pharma
1 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
: Galmed Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Medicus Pharma has a beta of -0.47, meaning that its share price is 147% less volatile than the S&P 500.
: 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Comparatively, 11.2% of Medicus Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Galmed Pharmaceuticals' return on equity of -29.43% beat Medicus Pharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Galmed Pharmaceuticals N/A -29.43% -26.00%
Medicus Pharma N/A -2,309.37% -284.09%
: In the previous week, Medicus Pharma had 3 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 4 mentions for Medicus Pharma and 1 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.00 beat Medicus Pharma's score of -0.07 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Galmed Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Medicus Pharma
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A
Medicus Pharma N/A N/A -$35.46M -$2.79 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%
Medicus Pharma	N/A	-2,309.37%	-284.09%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galmed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medicus Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.79	N/A

Summary

Galmed Pharmaceuticals beats Medicus Pharma on 8 of the 13 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to CytoMed Therapeutics?

Galmed Pharmaceuticals (NASDAQ:GLMD) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

: Galmed Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, CytoMed Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galmed Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
CytoMed Therapeutics
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: CytoMed Therapeutics' return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Galmed Pharmaceuticals N/A -29.43% -26.00%
CytoMed Therapeutics N/A N/A N/A
: 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
: In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 1 mentions for Galmed Pharmaceuticals and 0 mentions for CytoMed Therapeutics. Galmed Pharmaceuticals' average media sentiment score of 0.00 equaled CytoMed Therapeutics'average media sentiment score.
Company Overall Sentiment
Galmed Pharmaceuticals Neutral
CytoMed Therapeutics Neutral
: CytoMed Therapeutics has higher revenue and earnings than Galmed Pharmaceuticals.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A
CytoMed Therapeutics $250K 43.53 -$3.10M N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%
CytoMed Therapeutics	N/A	N/A	N/A

Company	Overall Sentiment
Galmed Pharmaceuticals	Neutral
CytoMed Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A
CytoMed Therapeutics	$250K	43.53	-$3.10M	N/A	N/A

Summary

Galmed Pharmaceuticals and CytoMed Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

Get Galmed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLMD vs. The Competition

Export

Metric	Galmed Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.23M	$3.11B	$6.28B	$11.90B
Dividend Yield	N/A	1.89%	2.74%	5.26%
P/E Ratio	-0.51	18.52	29.18	27.35
Price / Sales	N/A	312.11	507.94	85.59
Price / Cash	N/A	56.01	43.42	54.56
Price / Book	0.22	4.36	9.85	6.79
Net Income	-$10.31M	$72.19M	$3.55B	$332.68M
7 Day Performance	10.14%	3.06%	2.30%	2.55%
1 Month Performance	10.12%	7.96%	6.45%	9.36%
1 Year Performance	-51.33%	51.72%	44.89%	45.22%

Galmed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLMD Galmed Pharmaceuticals	0.4426 of 5 stars	$0.63 +6.4%	N/A	-56.4%	$3.23M	N/A	N/A	20	News Coverage
AIMD Ainos	0.7962 of 5 stars	$1.73 +1.2%	N/A	-34.4%	$12.43M	$120K	N/A	40	Positive News Upcoming Earnings
BCDA BioCardia	3.0775 of 5 stars	$1.10 -2.7%	$25.00 +2,172.7%	-54.3%	$12.36M	$60K	N/A	40	Upcoming Earnings
CLRB Cellectar Biosciences	3.2584 of 5 stars	$3.18 +12.4%	$11.00 +245.9%	-51.6%	$12M	N/A	N/A	10	News Coverage Upcoming Earnings Analyst Forecast High Trading Volume
MDCX Medicus Pharma	3.2735 of 5 stars	$0.28 -4.0%	$14.50 +5,172.7%	-92.0%	$11.98M	N/A	N/A	N/A	News Coverage Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLMD) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. AIMD, BCDA, CLRB, MDCX, and GDTC

How does Galmed Pharmaceuticals compare to Ainos?

Summary

How does Galmed Pharmaceuticals compare to BioCardia?

Summary

How does Galmed Pharmaceuticals compare to Cellectar Biosciences?

Summary

How does Galmed Pharmaceuticals compare to Medicus Pharma?

Summary

How does Galmed Pharmaceuticals compare to CytoMed Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. AIMD, BCDA, CLRB, MDCX, and GDTC

How does Galmed Pharmaceuticals compare to Ainos?

Summary

How does Galmed Pharmaceuticals compare to BioCardia?

Summary

How does Galmed Pharmaceuticals compare to Cellectar Biosciences?

Summary

How does Galmed Pharmaceuticals compare to Medicus Pharma?

Summary

How does Galmed Pharmaceuticals compare to CytoMed Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools